Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3176 |
|
Actual shortage: | 259 (8%) | |
Anticipated shortage: | 5 (0%) | |
Avoided shortage: | 9 (0%) | |
Resolved: | 2903 (91%) | |
Discontinuation Reports |
355 |
|
To be discontinued: | 22 (6%) | |
Discontinued: | 333 (94%) | |
Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
33 (12%) |
Shortage reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-LABETALOL | 100MG | TABLET | Resolved | 2023-06-16 | 2023-07-21 | 195069 |
APO-LABETALOL | 200MG | TABLET | Resolved | 2023-07-13 | 2023-07-21 | 198511 |
APO-LABETALOL | 200MG | TABLET | Resolved | 2023-11-10 | 2024-01-05 | 209964 |
APO-LABETALOL | 100MG | TABLET | Resolved | 2023-12-01 | 2024-01-05 | 212359 |
APO-LABETALOL | 200MG | TABLET | Resolved | 2024-06-20 | 2024-06-28 | 231030 |
APO-LABETALOL | 100MG | TABLET | Resolved | 2017-08-13 | 2021-01-11 | 19105 |
APO-LABETALOL | 200MG | TABLET | Resolved | 2017-08-13 | 2021-01-11 | 19108 |
APO-LAMIVUDINE | 150MG | TABLET | Resolved | 2017-03-11 | 2017-05-16 | 664 |
APO-LAMIVUDINE | 300MG | TABLET | Resolved | 2017-07-11 | 2017-08-31 | 15271 |
APO-LAMIVUDINE | 300MG | TABLET | Resolved | 2021-02-26 | 2021-06-28 | 134757 |
APO-LAMIVUDINE HBV | 100MG | TABLET | Resolved | 2019-12-05 | 2020-02-25 | 100278 |
APO-LAMIVUDINE HBV | 100MG | TABLET | Resolved | 2021-05-07 | 2021-06-28 | 138957 |
APO-LAMIVUDINE-ZIDOVUDINE | 300MG 150MG | TABLET | Resolved | 2017-12-06 | 2018-07-03 | 31907 |
APO-LAMIVUDINE-ZIDOVUDINE | 300MG 150MG | TABLET | Resolved | 2023-01-13 | 2023-01-20 | 181110 |
APO-LAMOTRIGINE | 150MG | TABLET | Resolved | 2019-01-03 | 2019-03-01 | 71130 |
APO-LAMOTRIGINE | 150MG | TABLET | Resolved | 2019-08-07 | 2019-08-21 | 91081 |
APO-LAMOTRIGINE | 25MG | TABLET | Resolved | 2019-09-04 | 2020-01-29 | 92978 |
APO-LAMOTRIGINE | 100MG | TABLET | Resolved | 2020-02-05 | 2020-03-27 | 105345 |
APO-LAMOTRIGINE | 100MG | TABLET TABLET | Resolved | 2020-05-08 | 2020-06-15 | 114288 |
APO-LAMOTRIGINE | 150MG | TABLET | Resolved | 2020-10-28 | 2020-12-07 | 127347 |
Discontinuation reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
APO-CAPTO TAB 6.25MG | 6.25MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60339 |
APO-CARVEDILOL | 12.5MG | TABLET | To be discontinued | 2024-01-26 | 2024-08-06 | 217493 |
APO-CARVEDILOL | 3.125MG | TABLET | To be discontinued | 2024-01-26 | 2024-01-26 | 217496 |